Company · PFE
Healthcare · 1 research article
Delayed up to 15 min · Source: Finnhub · Not investment advice
Pfizer's April 2026 patent settlements quietly pushed the Vyndaqel franchise cliff from 2029 to mid-2031 — while a 39%-growing Padcev franchise and a hidden obesity option in Metsera remain priced near zero. The market hasn't caught up.
| Company | View | Revenue YoY | EPS YoY | Guidance | Last report | |
|---|---|---|---|---|---|---|
| PFE Pfizer | LONG | — | — | — | — | |
| BMY Bristol-Myers Squibb | LONG | +7% | — | raised | Oct 29, 2026 | Compare |
| CVS CVS Health | LONG | +7.3% | — | raised | Aug 5, 2026 | Compare |
| DHR Danaher | LONG | +8.5% | — | revised | Oct 21, 2026 | Compare |
| HUM Humana | LONG | — | — | — | — | Compare |
| ISRG Intuitive Surgical | LONG | +22% | — | issued | Oct 20, 2026 | Compare |
| LLY Eli Lilly | LONG | +39% | +7% | raised | Oct 29, 2026 | Compare |
| MRK Merck | LONG | — | — | issued | Oct 29, 2026 | Compare |
Growth figures are year-over-year changes extracted automatically from each company's latest earnings release and can contain errors.
Widgets by TradingView. They load only when you click, so the page stays fast.
Forensic equity research on US stocks. No spam, unsubscribe anytime.
